Latest Breaking News On - Anita afzali - Page 2 : comparemela.com

Key Takeaways and Prospective Treatment Advances

David Hudesman, MD, Maia Kayal, MD, Miguel Regueiro, MD, Anita Afzali, MD, and Millie Long summarize their discussion of Inflammatory Bowel Disease (IBD) and discuss prospective advances in treatment options.

David-hudesman
Maia-kayal
Anita-afzali
Miguel-regueiro
Long-term-clinical-evidence
Inflammatory-bowel-disease
Prospective-treatment-advances
Millie-long

Treatment Approaches for Patients With UC

Treatment Approaches for Patients With UC
hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.

David-hudesman
Anita-afzali

Optimizing Therapies for CD

Optimizing Therapies for CD
hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.

Maia-kayal
Anita-afzali
David-hudesman
Miguel-regueiro

Selecting Treatments in Patients With EIM

Anita Afzali, MD, David Hudesman, MD, and Maia Kayal, MD, discuss how extra intestinal manifestations (EIM) affect therapy strategies for Crohn’s Disease (CD) patients.

David-hudesman
Anita-afzali
Maia-kayal
Crohns-disease
Cd
Extra-intestinal-manifestation
Eim
Rheumatoid-arthritis
Psoriasis
Tumor-necrosis-factor
Kntnf

The Role of Vedolizumab and Risankizumab in CD

Anita Afzali, MD, David Hudesman, MD, Millie Long, and Miguel Regueiro, MD, discuss Vedolizumab and Risankizumab as treatments for Crohn’s Disease (CD).

United-states
Miguel-regueiro
David-hudesman
Anita-afzali
Crohns-disease
Cd
Vedolizumab
Risankizumab
Risk-stratification
Bio-naïve-population
Tumor-necrosis-factor